Genotype 1 and Hepatitis C Treatment
The most common form of hepatitis C virus in the United States is genotype 1. About 50 percent of people with genotype 1 have a successful response to treatment with peginterferon and ribavirin. Many people with genotype 1 also benefit from taking a protease inhibitor or sofosbuvir. Other factors, such as the amount of virus in the body, can also influence how well a person responds to hepatitis C treatment.
How Genotype 1 Affects Hepatitis C TreatmentIf you are infected with genotype 1 of the hepatitis C virus (HCV), there are a few things you should know about the treatment for hepatitis C.
Genotype 1 is the most common form of HCV in the United States. It affects over 70 to 90 percent of the people in this country who have hepatitis C. It is estimated that up to 50 percent of the people with genotype 1 will have a sustained response (successful treatment) with peginterferon and ribavirin. Because of this relatively low success rate, it's recommended that a third type of medication, either a hepatitis C protease inhibitor (like Victrelis®, Incivek®, or Olysio™) or sofosbuvir (Sovaldi™), be added to boost the chance of success for people with genotype 1. Also, treatment may be longer for some regimens for those with genotype 1, compared with the other genotypes.
There are other factors that can also affect your chances of having a successful treatment, including:
- The particular regimen you are using
- The amount of virus in your body (see Hepatitis C Viral Load)
- How long you have had hepatitis C
- How much liver damage has already occurred
- Any other medical conditions you may have.
Since hepatitis C can affect people in different ways, be sure to discuss your individual situation with your healthcare provider.